HRS-4508 vs Trastuzumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
HRS-4508
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07003321 (registry estimate)
No aligned efficacy figure on record for this race.
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03505710 · Phase 2 · terminated
Participants were placed in cohorts by HER2 status and dose without randomization, nobody was blinded to treatment, and there was no comparison arm. Response rates were read by an independent central reviewer but are reported for each cohort on its own.
Next expected readout: December 2026 · NCT06250777 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70) (not_applicable)
Result source: NCT04644237
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRS-4508 | Trastuzumab Deruxtecan |
|---|---|---|
| PFS, median | —Not reported | 9.5bNCT046442371 other result
|
| OS, median | —Not reported | 17.9bNCT046442371 other result
|
| ORR | —Not reported | 56%bNCT046442373 other results
|
| Duration of response, median | —Not reported | 12.9bNCT046442371 other result
|
PFS, median
- HRS-4508
- —Not reported
- Trastuzumab Deruxtecan
- 9.5bNCT04644237
1 other result
- 9.7 NCT04644237
OS, median
- HRS-4508
- —Not reported
- Trastuzumab Deruxtecan
- 17.9bNCT04644237
1 other result
- 19 NCT04644237
ORR
- HRS-4508
- —Not reported
- Trastuzumab Deruxtecan
- 56%bNCT04644237
3 other results
- 50% NCT04644237
- 56% NCT04644237
- 46.1% NCT04644237
Duration of response, median
- HRS-4508
- —Not reported
- Trastuzumab Deruxtecan
- 12.9bNCT04644237
1 other result
- 11.1 NCT04644237
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-4508: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HRS-4508: 0 of 4 rows · Trastuzumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Trastuzumab Deruxtecan |
|---|---|
| Dropout rate | n/a: no completion milestone6.4 mg/kga NCT04644237 · Phase 2 show 1 more resultn/a: no completion milestone5.4 mg/kg NCT04644237 · Phase 2 |
| Discontinued due to AEs | 38%6.4 mg/kga NCT04644237 · Phase 2 show 1 more result17.6%5.4 mg/kg NCT04644237 · Phase 2 |
| Serious AEs | 52%6.4 mg/kga NCT04644237 · Phase 2 show 1 more result41.6%5.4 mg/kg NCT04644237 · Phase 2 |
| Most frequent reported AEs | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trastuzumab Deruxtecan
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-4508's landscape · Trastuzumab Deruxtecan's landscape